Enfortumab vedotin (EV) is a groundbreaking ADC therapy targeting metastatic bladder cancer, specifically designed to bind to Nectin‐4, a cell adhesion molecule highly expressed in urothelial carcinoma. The gene discussed is NECTIN4; the disease is urinary bladder carcinoma.